LAFAYETTE, Colo.--(BUSINESS WIRE)--The Center for Disease Analysis Foundation (CDA Foundation) is thrilled to announce the first-round recipients of the CDAF-Relink grant to connect Hepatitis B and C infected individuals in the United States back to care. The program is funded by an eight-million-dollar grant from Gilead Sciences (Nasdaq: GILD) as part of Gilead’s Relink grant program. In this first round, CDA Foundation distributed a total of 2.1 million dollars to the following 14 grantees: Organizat ...

Gilead Sciences, Inc. (NASDAQ:GILD) Barclays 26th Annual Global Healthcare Conference March 13, 2024 11:15 AM ET Company Participants Andy Dickinson - CFO Conference Call Participants Carter Gould - Barclays Carter Gould Good afternoon. Welcome to Day 2 of the Barclays Global Healthcare Conference. My name is Carter Gould, covering U.S. biopharma. I am pleased to welcome Gilead Sciences to the stage. Joining us from the company, Andy Dickinson, CFO. Andy, you’re going to make some opening comments, and the ...

Gilead Sciences, Inc. (NASDAQ:GILD) Leerink Partners Global Biopharma Conference March 12, 2024 10:00 AM ET Company Participants Cindy Perettie - EVP, Kite Conference Call Participants Daina Graybosch - Leerink Partners Daina Graybosch Okay. Good morning, everyone. My name is Daina Graybosch. I am an analyst here at Leerink Partners. My team and I cover immuno-oncology and broader. And we -- one of the companies we cover is Gilead, and we're really excited today to host Cindy Perettie from Kite. Cindy Peret ...

Gilead Sciences, Inc. (NASDAQ:GILD) Leerink Partners Global Biopharma Conference March 12, 2024 10:00 AM ET Company Participants Cindy Perettie - EVP, Kite Conference Call Participants Daina Graybosch - Leerink Partners Daina Graybosch Okay. Good morning, everyone. My name is Daina Graybosch. I am an analyst here at Leerink Partners. My team and I cover immuno-oncology and broader. And we -- one of the companies we cover is Gilead, and we're really excited today to host Cindy Perettie from Kite. Cindy Peret ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Gilead’s cash tender offer for CymaBay Therapeutics, Inc. expired at 11:59 p.m. on March 8, 2024. On February 22, 2024, Gilead and CymaBay filed the Premerger Notification and Report Forms required under the HSR Act with the Federal Trade Commission and the Antitrust Division of the U.S. Departmen ...

In the latest trading session, Gilead Sciences (GILD) closed at $73.66, marking a +1.42% move from the previous day. The stock outpaced the S&P 500's daily gain of 1.03%. Meanwhile, the Dow gained 0.34%, and the Nasdaq, a tech-heavy index, added 1.51%.Prior to today's trading, shares of the HIV and hepatitis C drugmaker had lost 2.41% over the past month. This has lagged the Medical sector's gain of 2.1% and the S&P 500's gain of 3.21% in that time.Investors will be eagerly watching for the performance of G ...

Gilead Sciences (GILD) and Merck (MRK) announced promising first data from a phase II study evaluating the combination of a once-weekly treatment regimen of Merck’s islatravir and Gilead’s lenacapavir.The data demonstrated the efficacy of this potential long-acting oral combination treatment option in maintaining viral suppression in individuals with HIV.At the 24-week mark, the combination of islatravir and lenacapavir showcased an impressive 94.2% rate of viral suppression (HIV-1 RNA <50 copies/mL), with ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from three studies evaluating the efficacy and safety profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) for a broad range of people with HIV, including those with HIV/hepatitis B (HBV) coinfection and HIV/tuberculosis (TB) coinfection. These data and other studies supporting the important role of Biktarvy in the HIV treatment landscape were presented at ...

FOSTER CITY, Calif., & RAHWAY, N.J.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 2 clinical study evaluating the investigational combination of islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a first-in-class capsid inhibitor. These late-breaking data were presented during an oral session at the 31st Conference on Retroviruses ...

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this HIV and hepatitis C drugmaker have returned -6.1% over the past month versus the Zacks S&P 500 composite's +2.9% change. The Zacks Medical - Biomedical and Genetics industry, to which Gilead belongs, has gained 1% over this period. Now the key question is: Where could the stock be ...